Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxybutynin Chloride Extended-Release Tablets to Improve Early Continence Recovery After Robotic Prostatectomy
NCT06966778Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of oxybutynin in urinary incontinence (UI) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Number of Participants Achieving Urinary Continence (0-1 Pad/Day) at 12 months. Started Sep 2025; status: recruiting.
02
Drugs
oxybutynin
03
Conditions
urinary incontinence (UI)
Beyond the preview
Go deeper on NCT06966778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966778.